nemiralisib groups were higher than in placebo group. Cough was the most common
non-serious side effect in all the treatment groups.
Are there plans for further studies?
Other studies on nemiralisib in patients with COPD have been conducted. No further
studies are planned at this time.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study numbers associated with this study are
shown below with internet links to scientific summaries and other information.
The scientific summaries include more details about the requirements for study
enrolment, the study visit schedule, results from other endpoints, and more detailed
information about adverse events.
Organisation Website Study Number
European Medicines
www.clinicaltrialsregister.eu 2017-001074-421
Agency
United States National
www.clinicaltrials.gov NCT033454072
Institutes of Health (NIH)
Your doctor can help you understand more about this study and the results. Speak to
your doctor about the treatment options available in your country. You should not
make changes to your care based on the results of this or any single study. Keep taking
your current treatment unless instructed by your doctor.
We would like to thank the patients who contributed to this study. The results of this
study will help answer scientific questions about treating patients with COPD.
The content for this document was finalised by GSK on the 18th of November 2019. The
information in this summary does not include additional information available after this
date.
1https://www.clinicaltrialsregister.eu/ctr-search/search?query=200879
2https://clinicaltrials.gov/ct2/show/NCT03345407?term=NCT03345407&rank=1